Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Equal-Weight on Adobe, Lowers Price Target to $330

Barclays analyst Saket Kalia maintains Adobe (NASDAQ:ADBE) with a Equal-Weight and lowers the price target from $340 to $330.
byBenzinga Newsdesk
October 13, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Barclays analyst Saket Kalia maintains Adobe (NASDAQ:ADBE) with a Equal-Weight and lowers the price target from $340 to $330.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Atea Pharmaceuticals Announced The Presentation Of New Phase 1, In Vitro And In Vivo Data That Demonstrate Key Profile Attributes Of Atea’s Lead Drug Candidate, Bemnifosbuvir, For Covid-19 And Hepatitis C

By Benzinga Newsdesk
March 14, 7:18 AM
Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies Bemnifosbuvir retains activity against all SARS-CoV-2 variants of concern evaluated as well as

AVIR